Medikinet

Methylphenidate, the active ingredient in Medikinet, is a psychostimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults.

GNH USA supplies Medikinet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medikinet, a methylphenidate product, is used in conditions involving central nervous system stimulation.

- Attention Deficit Hyperactivity Disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in children, adolescents and adults. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or nausea.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychotic symptoms: hallucinations, delusions, or severe agitation. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Before prescribing Medikinet, several precautionary measures should be considered.

- Cardiovascular assessment: evaluate heart disease, hypertension, or arrhythmias before initiation. - Psychiatric history: screen for anxiety, tics, or a history of psychosis. - Growth monitoring: regularly assess height and weight in children and adolescents. - Substance abuse potential: consider risk of misuse or dependence, especially in adolescents. - Drug interaction review: avoid concurrent use with monoamine oxidase inhibitors or other stimulants. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Methylphenidate can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Certain antipsychotics (e.g., haloperidol): can reduce stimulant effectiveness.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may enhance serotonergic activity. - Antihypertensive agents: methylphenidate may diminish blood pressure control. - Antacids: can affect absorption of the oral formulation. - Alcohol: may exacerbate central nervous system stimulation. - Seizure medications: potential for lowered seizure threshold.